Current and Potential Antiarrhythmic Drugs Targeting Voltage-Gated Cardiac Ion Channels

Mathew Perez-Neut, Vidhya Rao, Lauren Haar, Keith W Jones and Saverio Gentile*
Department of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Maywood, IL USA

Abstract

Voltage-gated ion channels play a fundamental role in the generation and propagation of the cardiac action potential by acting synergistically to produce an ionic current across cellular membranes. Abnormalities of heart ion channel activities that lead to loss or gain of function (channelopathies) are often associated with disruption of the coordinated propagation of electrical activity of the cardiac myocytes and can generate fatal arrhythmogenesis. Drugs that act on cardiac ion channels have long been used to restore normal rhythm and conduction in patients affected by cardiac arrhythmias and offered to basic scientists the possibility to characterize distinct ion channel classes. This review will explore the mechanisms and role of the current anti-arrhythmic drugs used in the clinic, and discuss recent development on ion channel openers as potential anti-arrhythmic drugs.

Abbreviations: VGIC: Voltage gated ion channels; VGKC: Voltage gated potassium channels; KCNQ: Potassium Channel, Voltage-Gated, KQT-like subfamily; KCN: Potassium channel voltage gated subfamily H; ATP: Adenosine tri phosphate; hERG1: human Ether-a-go-go-Related Gene; SCN: Sodium channel, voltage gated; CACNA: Calcium channel, voltage gated [gene]; CaV: Calcium channel, voltage gated [protein]; RyR: Ryanodine receptor channel family (‘funny’ Na* channels) [7] through which sodium ions slowly cross the membrane (Na* currents) until the membrane potentials reach a value that activates the fast Na* channel [8]. Consequently, the rapid Na* entry quickly depolarizes the cell membrane (phase 0) reaching up to values of 20-25 mV. At this membrane potential, the inactivation gate of the fast Na* channels closes (inactivated state) producing an impermeable channel that can re-open only when the membrane potential reaches the values at rest [9]. This phenomenon underlines the initiation of the refractory period during which the cardiac cell cannot elicit another action potential. However, although in the refractory period, random refractory period during which the cardiac cell cannot elicit another action potential can lead to generation of a small Na* current (late current, I_{Na}) that appears to contribute minimally in shaping the action potential of a normal cardiac myocyte but may play an important role in a diseased heart [10-12].

Closing of the Na* channels in addition to the slow opening of Cl* (inward flow of negative charges) [13-15] and potassium channels (outward flow of positive charges) determines the initial descending deflection of the cardiac action potential (phase 1) [16]. This event is followed by a plateau (phase 2) in which an inward Ca++ currents resulting from activation of L-type calcium channels [17-19] is balanced by an outward K+ current upon activation of KCNQ and KCNH type potassium channels [16]. During this phase, cells accumulate Ca++ that is used in conjunction with ATP during the activation of the contractile machinery (systole).

Finally, closure of the Ca++ channels determines the initiation of repolarization that is progressively accelerated by the full activation of potassium channels such as the KCNH (hERG1) channels (phase 3) [16]. As the membrane potential repolarizes, several potassium channels close resulting in restoring the resting membrane potential. At this point, the funny Na* channels can re-open until a new phase 4 initiates.

Aberrant cardiac ion channel activities can often be associated with generation of an abnormal action potential that results in arrhythmias [20-23]. For example, malfunction of several ion channels including Na*, K+ or Cl- channels can lead to a pathological retardation in the repolarization of the cardiac action potential. This phenomenon is detected as prolonged QT interval measured by electrocardiogram (Long QT Syndrome, LQT) [24], and is the lead culprit in polymorphic ventricular tachycardia—the classical arrhythmia (Table 1).

Antiarrhythmic drugs aim to abolish the electrophysiological
mechanisms that are responsible for the cardiac arrhythmias. These drugs can exhibit diverse properties according to their effects on the targeted ion channels as they and can be channel blockers (ligands that block ionic flows), gating inhibitors (ligand that inhibit channel gating either by acting on ion channel activation or inactivation) or activators (ligands that activate ion channels by direct binding) [25,26].

Pharmacology of the Cardiac Na⁺ Channel

Nine genes in the human genome (SCN1A through SCN9A) encode for Na⁺ channel α subunit proteins named Na⁺.1.1 through Na⁺.1.9 and 4 β subunits (SCN1B-SCN4B). Although mRNA for several Na⁺ channels have been found in the human heart, the product of the SCN5A gene, Na⁺.1.5, is considered the main Na⁺ channel that determines excitability and electrical conduction velocity in the cardiac myocytes. This conclusion is centered on the observation that mutations of the Na⁺.1.5 channel that cause partial or complete loss of Na⁺.1.5 activity can cause a delay of depolarization during phase 0 of the action potential [27-31]. This is hypothesized to occur by enhancing Iₙ, which can lead to an abnormal Ca²⁺ entry during phase 2 or phase 3 upon reactivation of Ca²⁺ channels that has been related to clinically relevant cardiac arrhythmias such as Brugada syndrome (Table 1) [32-34].

Na⁺.1.5 channel blockers

Class 1 antiarrhythmic drugs (Vaughan-Williams Classification [35]) target the fast acting cardiac Na⁺ channels during phase 0. These drugs cause inhibition of membrane permeability to Na⁺ by acting as Na⁺ channel blockers, thereby decreasing rate/velocity/magnitude of the depolarization that occurs in phase 0 of the cardiac action potential [36]. Since activity of Na⁺ channel determines the speed through which a cardiac action potential depolarizes inhibition of Na⁺ channels is a common strategy used to correct disturbances of the heart rhythm in which the heart rate is abnormally increased (pathological tachycardia/tachyarrhythmia). Members of the Class 1 antiarrhythmic drugs are divided into three different categories (1A, 1B, 1C) and are defined by the different degree of Na⁺ channel blockade.

Procainamide or quinidine is Class IA antiarrhythmic drugs indicated for the treatment of sustained ventricular fibrillation. The effects of these Na⁺ channel blockers is reduction of cell excitability by increasing the threshold for the rapid depolarization during phase 0. Consequently, termination of the refractory period of the atria and ventricles is delayed. However, these drugs can also be pro-arrhythmic and are contraindicated by the presence of prolonged QT [37].

Lidocaine is one of the most commonly used class IB antiarrhythmic. This drug blocks Na⁺ channel in the conduction system and in the muscle cells of the heart causing inhibition of spontaneous depolarization during diastole [38,39].

Flecainide and Propafenone are examples of class IC antiarrhythmic drugs approved for the treatment of ventricular arrhythmias [40-42]. The overall effects of these Na⁺ channel blockers results in inhibition of electrical conduction in the whole heart that causes a reduction of action

<table>
<thead>
<tr>
<th>Arrhythmia</th>
<th>Description</th>
<th>Mutation</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brugada Syndrome</td>
<td>Abnormal ECG</td>
<td>Na⁺.1.5</td>
<td>SCN5A   Na⁺ Channel α subunit</td>
</tr>
<tr>
<td></td>
<td>Increased sudden cardiac death</td>
<td>SCN1B</td>
<td>SCN1B   Na⁺ Channel β subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Na⁺.1.8</td>
<td>SCN10A  Na⁺ Channel α subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAD1</td>
<td>GPD1L   Nav1.5 Accessory subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHF1</td>
<td>HEY2    Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ca⁺.1.2</td>
<td>CACNA1C Ca⁺ Channel α subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CACNB2</td>
<td>CACNB2  Ca⁺ Channel β subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KCNE3</td>
<td>KCNE3   Kv.4.3 Channel β subunit</td>
</tr>
<tr>
<td>Long QT Syndrome (LQT)</td>
<td>Long QT interval,</td>
<td>Kᵥ7.1</td>
<td>KCNO1  K⁺ channel α subunit</td>
</tr>
<tr>
<td></td>
<td>Normal heart rate,</td>
<td>Kᵥ11.1</td>
<td>KCNH2   K⁺ channel α subunit</td>
</tr>
<tr>
<td></td>
<td>Normal heart structure</td>
<td>Na⁺.1.5</td>
<td>SCN5A   Na⁺ Channel α subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ankirin-B</td>
<td>ANK2    Nav1.5 anchoring protein</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MIRP</td>
<td>KCNE1   Kᵥ7.1 Channel β subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MINK</td>
<td>KCNE2   Kᵥ11.1 Channel β subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kir2.1</td>
<td>KCNJ2   K⁺ channel α subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ca⁺.1.2</td>
<td>CACNA1C Ca⁺ Channel α subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caveolin 3</td>
<td>CAV3    Scaffolding protein</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SCN4B</td>
<td>SCN4B   Na⁺ Channel β subunit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A⁺-Kinase anchor protein</td>
<td>AKAP9  Anchoring protein</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A⁺1-syntrophin</td>
<td>SNTA1 Nav1.5 anchoring protein</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kir3.4</td>
<td>KCNJ5   G protein-activated rectifier K⁺ channel (GIRK)</td>
</tr>
<tr>
<td>Short QT Syndrome (SQT)</td>
<td>Short QT interval,</td>
<td>Kᵥ11.1</td>
<td>KCNH2   K⁺ channel α subunit</td>
</tr>
<tr>
<td></td>
<td>Normal heart rate,</td>
<td>Kᵥ7.1</td>
<td>KCNO1  K⁺ channel α subunit</td>
</tr>
<tr>
<td></td>
<td>Normal heart structure</td>
<td>Kir2.1</td>
<td>KCNJ2   K⁺ channel α subunit</td>
</tr>
</tbody>
</table>

Table: 1 The classical Arrhythmia
Potential frequency without changes in action potential duration. This is most probably achieved by inhibition of the Na⁺ currents more than its effects on peak currents. However, these drugs are mostly used in structurally normal hearts.

Binding of Na⁺.5 blockers to the target are associated with the conductive status of the channel as their binding affinities strongly increase with opened or inactivated channels due to improved access to specific binding sites. Class I antiarrhythmic drugs bind Na⁺.5 during depolarization of the phase 0 more than at resting membrane potentials. The clinical efficacy of a class I antiarrhythmic drugs is mostly related to its unbinding kinetics and the choice of treatment is strongly dependent from the heart condition [43]. For example, lidocaine presents a rapid binding and unbinding kinetics and it can be considered as a pure I[(Na⁺.5)] blocker [44]. However, lidocaine is not very effective in suppressing atrial fibrillation (AF) [43]. In contrast BAY K 8644 or propafenone have a slower binding and unbinding kinetics for Na⁺ channels compared to lidocaine and it is clinically effective in restoring heart function during AF. In addition, these latter drugs can also inhibit other ion channels that are important for the development of a cardiac action potential.

**Na⁺ channel activators**

More than one hundred mutations in the SCN5A gene have been described as the cause of a pathological inhibition of the Na⁺.5 activity [27-31]. Therefore, therapeutic use of Na⁺.5 opens appears to be the most logical step to improve cardiac performance in for example Brugada or LQT3 patients. Unfortunately, few cardiac Na⁺ ion channel activators have been developed or discovered and very little is known about the therapeutic possibilities of such compounds.

One of the side effects of positive inotropic agents such as the sympathomimetic dobutamine, is related to appearance of ventricular arrhythmia. Interestingly, one study compared the effects of Na⁺ channel activator LY341311 to dobutamine and showed that LY341311 effectively counteracted heart failure prolongation of the QT interval or revealed evidence for arrhythmogenicity [45].

Another compound, KB130015 [46], has the unique ability to act as a Na⁺ channel activator in a dose dependent fashion. KB130015 inhibits the Na⁺ ion channel inactivation phase, thereby causing the Na⁺ ion channel to remain in an open state for longer. Paradoxically, this cause shortening of the action potential duration, suggesting that this compound can be used to minimize the length of the action potentials in tachycardia. However, KB130015 shows a significant promiscuity toward other ion channels involved in the cardiac action potential, and should therefore be investigated more carefully [46].

A number of mutations on SCN5A gene lead to dysregulation of Na⁺.5 trafficking to the surface membrane resulting in reduced Na⁺ current amplitude [47]. In this case, use of Na⁺.5 activators appears to be a promising prospective as they could compensate for the loss of Na⁺ permeability and possibly restore cardiac function. Furthermore, it has been shown that, Mexiletine (a class IB antiarrhythmic drug) can improve membrane density of trafficking-deficient Na⁺.5 channels suggesting that normal cardiac Na⁺.5 function could be rescued by drugs that promote trafficking [48,49]. However, the effects of Mexiletine as Na⁺.5 trafficking-deficient rescuer could be overruled by its properties as Na⁺.5 blocker and more critical studies need to be developed [50].

The slow inward Na⁺ channel activator Ibutilidine is the only pure class III antiarrhythmic drug that has been approved for acute conversion of atrial fibrillation to normal sinus. This drug selectively enhances I[B] and results in prolongation of the cardiac action potential and refractory period [51].

**Pharmacology of the Cardiac Calcium Channel**

Similar to Na⁺ channels, several human genes (CACNA1A through CACNA1G and CANCA1S) encode for multiple distinct voltage-gated Ca²⁺ channels (Ca₁.2, Ca₁.3, Ca₁.4; Ca₂.1, Ca₂.2, Ca₂.3; Ca₃.1, Ca₃.3). However, only Ca₁.2 channel (alias low-threshold Ca₉ channel; L-type) that is encoded by CACNA1C plays a role in the development of the cardiac action potential. Opening of the L-type calcium channel is essential to couple excitation to contraction as the inward Ca²⁺ currents initiate the release of Ca²⁺ from the sarcoplasmic reticulum by activating ryanodine receptors via a process called calcium-induced calcium release (CICR) [52]. This self-sustained increase in intracellular Ca²⁺ causes the plateau in the of the cardiac action potential shape and allows contraction of the cardiac myocytes [53].

**L-type Ca⁺⁺ channel blocker**

Although several L-type calcium channel blockers or gating inhibitors have been synthesized, only two members of the class IV antiarrhythmic drugs namely, verapamil and diltiazem, have been approved for clinical treatment of cardiac arrhythmia [54-57]. Similar to drugs targeting Na⁺ channels, verapamil and diltiazem bind Ca₁.2 channel in its open state and exhibit "use dependence" with higher binding affinity at higher stimulation frequency [58]. Verapamil or diltiazem are primarily effective on tissues that present electrophysiological properties of a Ca²⁺ driven action potential (slow action potential). Therefore, it is mainly used to treat malfunctions of sinoatrial or atrioventricular nodes (e.g. paroxysmal supraventricular tachycardia), since their activity strongly depend upon calcium entry.

**L-type Ca⁺⁺ channel activator**

Reduced L-type Ca₁.2 density and regulation are thought to contribute to the disturbed Ca²⁺ handling during cardiac arrhythmia. For example, one of the frequent causes of action potential shortening during atrial fibrillation is a reduction of Ca₁.2.2 protein synthesis [59]. Therefore, stimulation of the L-type Ca²⁺ currents could be a possible approach to improve cardiac contractility in a failing heart [60]. Although not in large number, L-type Ca₁.2 channels activators have been used extensively to study function of the L-type currents. Dihydropyridines such as BAY K 8644 has proven to be excellent Ca₁.2 channel agonists in both animal model and isolated human cardiac myocytes. Interestingly, in these studies the BAY K 8644-dependent increase in inotropic effects on failing heart was reduced compared to a normal heart [61]. Nevertheless, use of adrenergic agonists partially rescued the limited effect of BAY K 8644 on failing heart.

One of the most common problems in using cardiotoxic agents that acts on heart sarclemma Ca²⁺ channels is calcium overload. The increased intracellular calcium, produced by for example glycosides, can cause arrhythmias. Thus, they have a low therapeutic index [62]. Interestingly, BAY K 8644 determines an increase of Ca²⁺ entry only at the beginning of the systole (50 ms; phase 2) with progressively smaller contribution during the plateau and has no effects on calcium entry during diastole. This phenomenon is probably due to the fast kinetics of recovery from blocking Ca₁.2. The small increase in Ca²⁺ entry produces no significant contribution in activating myofibrils but could certainly facilitate the Ca²⁺ release form sarcoplasm. Traditionally, arrhythmogenic disorders associated with deranged Ca²⁺ release from the sarcoplasmic reticulum have been associated with gain-of-function
mutations on ryanodine receptors (RyR) that generates excessive Ca2+-leak from the intracellular store such as the sarcoplasmic reticulum. However, recent investigations started challenging this view as they report that a loss-of-function mutation on RyR type 2 (the most expressed in cardiac cells) is associated with sudden cardiac death [63]. This suggests that BAY K 8644-like drugs could be potentially used to treat cardiac arrhythmias associated with depressed sarcoplasmic Ca2+-release possibly due to loss-of-function mutations on ryanodine receptors. The rational for the use of Ca1.2 activators as therapeutic approach to treat cardiac arrhythmias needs to accurately contemplate the possibility of severe side effects as besides the heart, Ca1.2 plays a major role in several organs including brain and smooth muscles.

**Pharmacology of the Cardiac Potassium Channel**

The human genome comprises of circa 80 genes that encode for potassium channels among which many voltage-gated potassium channel (VGKC) are expressed in the heart.

The VGKC that play a major role in controlling the heart action potential belong to several sub-categories which comprise of members that are characterized by different biophysical parameters.

The Kv1.4, Kv4.2 and Kv4.3 are the main molecular contributor to the development of an outward K+ current (I\textsubscript{k}) that counteracts the fast depolarization during phase 0 [64,65].

During phase 3 of the cardiac action potential an outward K+-flux (I\textsubscript{k}) determines repolarization of the membrane and strongly contributes to restore resting membrane potential. Activity of several K+ channels contribute to the development of the IK which can be divided in three distinct components: ultrafast (I\textsubscript{k,ultra}) [66], rapid (I\textsubscript{k,r}) [67] and slow (I\textsubscript{k,s}) [68] component according to what cardiac cells are examined.

The K1.5 channel is the major contributor for the I\textsubscript{k,ultra} and it is exclusively expressed in the atria (no I\textsubscript{k,ultra} current is detectable in the ventricle), while Kv11.1 (alias hERG1 channel) and Kv7.1 respectively control the I\textsubscript{k,r} and slow I\textsubscript{k,s} currents in several cardiac cells.

**I\textsubscript{k} current blockers**

Changes in Kv1.4, Kv4.2 or Kv4.3 potassium channels current densities can strongly alter activity of the L-type Ca2+-channels and therefore these K+ channels can alter intracellular Ca2+ level during phase 2. For example, mutations on Kv4.3 channel that leads to increased I\textsubscript{k} have been associated with Brugada syndrome [69]. Several class I antiarrhythmic drugs including quinidine and flecainide have been shown to inhibit I\textsubscript{k} current with similar potency in human and other mammalian heart and to be effective in controlling AF. However, due to concerning pro-arrhythmic effects and the development of better drugs, quinidine is mostly limited to treatment of vagally mediated AF.

**I\textsubscript{k,ultra} current blockers**

Class I and class III antiarrhythmic drugs have proven to be important tools but their action is limited to immediate treatment as they can produce fatal ventricular arrhythmias in the long-run. Studies indicate that this effect is due to the heterogeneity of the cardiac ventricular ion channel population and promiscuity of the drug in use. Therefore, targeting an ion channel with preferential expression in atrial tissue may provide a better therapeutic approach for the suppression of cardiac arrhythmias. Tests on the effects of several Kv1.5 blockers on heart function have revealed that these drugs do not alter repolarization of the cardiac action potential (normal QT interval) and restores the sinus rhythm during AF [70]. Interestingly, it has been shown that propafenone (class 1C antiarrhythmic) exhibits blocking activity on Kv1.5 channel suggesting that this event could contribute to the efficacy of propafenone in correcting paroxysmal AF [71,72]. Both gain and loss-of-function mutations in Kv1.5 channel have been found in patients affected by early-on-set lone AF which confirms the hypothesis that alteration of the I\textsubscript{k,ultra} current can be associated with AF [73,74]. While no Kv1.5 channel activators have been identified yet, use of Kv1.5 blockers appears to be promising for treatment of some cardiac arrhythmias however, clinical data are still missing.

**I\textsubscript{k,r} current blockers**

The human Ether-a-go-go Related Gene (hERG1) encodes for a 6 transmembrane a subunit of 1159 amino acids that assembles as tetramer on the surface membrane of several cardiac cells to form a voltage-gated potassium ion channel (Kv11.1). Activity of Kv11.1 plays a fundamental role during the repolarization phase of the cardiac action potential (phase 3).

Members of the methane sulfonamide group of the class III anti-arrhythmic drugs target Kv11.1 in a use-dependent manner as they preferentially bind the channel in its open state [75,76]. Consequently, they produce an elongation of the repolarization phase (phase 3) of the atrial and ventricular cardiac action potential and extend the refractory time. However, they can also exhibit reverse-use dependence on the action potential as they can affect other ion channels as well [77]. Therefore, although Kv11.1 blockers can exhibit notable differences, they are the commonly used drugs to prevent cardiac arrhythmias.

Amiodarone is the preferred drug for prevention of AF and it is under evaluation as a prophylactic therapy to prevent AF after cardiac surgery [78,79]. Although amiodarone is a Kv11.1 channel blocker, the incidence of ventricular fibrillation associated with amiodarone is very low compared to other class III anti-arrhythmic drugs. This is probably due to the inhibitory effect of amiodarone on Ca2+ channel activity that results in shortening of the duration of the action potential and therefore, counteracts the effects of amiodarone on Kv11.1 [80]. However, the inhibitory effects of amiodarone on Ca2+-permeability have been associated with a significantly higher incidence of bradycardia [81-83]. Other important side effects of amiodarone are not necessarily related to its action on the Kv11.1 channel, and include pulmonary toxicity, hepatotoxicity, reduced visual acuity, optic nerve injury, ataxia, sexual and gastrointestinal dysfunctions [84].

Dofetilide is a pure class III antiarrhythmic drug as it selectively blocks Kv11.1 and it is used with patients with AF [85]. However, the risk of drug-induced ventricular fibrillation is higher compared to amiodarone, although still rare [86].

Many therapeutic drugs used to treat different health conditions such as allergies, gastrointestinal or psychiatric disorders have been withdrawn from the market because of the severe inhibitory effects on Kv11.1 channel resulting in acquired-LQT2 (aLQT2). However, side effects of antiarrhythmic drugs targeting Kv11.1 channel can also result from the presence of the channel in extra heart tissues. For example, it has been shown that aLQT2 induced by some anti-epileptic drugs such as phenytoin or trimethadione [87] or even the class III anti-arrhythmic almokalant strongly associate with teratogenesis [88,89]. In contrast, stimulation of Kv11.1 channel inhibits proliferation of breast cancer cells [90,91]. These events imply that aberrant changes of Kv11.1 electrical activity can play an important role also outside the heart.

**I\textsubscript{k,s} current activators**

Screening of unrelated individuals affected by LQT2 syndrome
has revealed at least 290 loss-of-function and surprisingly one gain-of-function mutations on the hERG1 gene [92]. It is not understood why hERG1 gene is highly susceptible to genomic variation or drug targeting but this fact alone inspires the need to address the therapeutic value of potassium channel activators as anti-arrhythmic agents. The first Kv1.1 channel activator was discovered by David Rampe group who reported that the synthetic compound RPR260243 [93] significantly slowed deactivation of Kv1.1 which translates in an overall larger K+ outward current during phase 3 of the cardiac action potential resulting in a faster repolarization. Since then, other Kv1.1 channel activators have been discovered acting via diverse mechanisms. For example, NS1643 [94, 95] increases Kv1.1 currents by inhibiting inactivation of the channel. Interestingly, these Kv1.1 activators presented no severe effects on healthy animal hearts while they were able to rescue the effects of Kv1.1 blockers by shortening the QT interval. Furthermore, the non-steroidal anti-inflammatory drugs flufenamic and niflumic (which share high homology structure with NS1643) do not present any effects on heart function although they exhibit stimulatory effects on Kv1.1 channel activity [96]. This suggests the possibility that, Kv1.1 channel activator could be considered as therapeutic agents for the treatment of repolarization disorders in the heart including LQT syndrome.

References


